Holen Sie sich die Stockscreener-App
17.14
0.18%
0.03
Handel nachbörslich:
17.48
0.34
+1.98%
Schlusskurs vom Vortag:
$17.11
Offen:
$17.19
24-Stunden-Volumen:
1.38M
Relative Volume:
1.40
Marktkapitalisierung:
$2.29B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-151.09M
KGV:
-10.99
EPS:
-1.56
Netto-Cashflow:
$-160.51M
1W Leistung:
+0.00%
1M Leistung:
+18.78%
6M Leistung:
-2.72%
1J Leistung:
+55.68%
1-Tages-Spanne:
$16.81
$17.75
1-Wochen-Bereich:
$16.25
$17.75
52-Wochen-Spanne:
$9.60
$19.09
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Firmenname
Centessa Pharmaceuticals Plc Adr
Sektor
Branche
Telefon
44 7391 789784
Adresse
3RD FLOOR, ALTRINCHAM, CHESHIRE
Vergleichen Sie CNTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
17.14 | 2.29B | 0 | -151.09M | -160.51M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-05-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-19 | Eingeleitet | B. Riley Securities | Buy |
| 2024-07-18 | Eingeleitet | Oppenheimer | Outperform |
| 2023-11-15 | Hochstufung | Jefferies | Hold → Buy |
| 2023-10-26 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-06-21 | Eingeleitet | Evercore ISI | Outperform |
| 2023-06-12 | Eingeleitet | Guggenheim | Buy |
| 2023-03-17 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-12 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-06-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Centessa Pharmaceuticals Plc Adr Aktie (CNTA) Neueste Nachrichten
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 - Placera.se
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 - GlobeNewswire Inc.
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Recommendation of “Buy” by Brokerages - Defense World
Bank of New York Mellon Corp Buys Shares of 10,257 Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) - Defense World
The Future of Centessa Pharmaceuticals plc ADR: Analyzing CNTA - investchronicle.com
Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares By Investing.com - Investing.com India
Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares - Investing.com
Cerity Partners LLC Invests $471,000 in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) - Defense World
Centessa Pharmaceuticals plc ADR Inc. (CNTA) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Taseko Mines Ltd: Navigating Market Fluctuations with a 1.09B Market Cap - investchronicle.com
Codere Online Luxembourg (NASDAQ:CDRO) & Take-Two Interactive Software (NASDAQ:TTWO) Critical Analysis - Defense World
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of “Buy” by Analysts - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 3.8% After Insider Selling - Defense World
Centessa Pharmaceuticals’ Accardi sells $210,000 in shares - Investing.com
Centessa Pharma CEO Saha sells $694,826 in shares - Investing.com
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Centessa Gets US FDA's Clearance to Start Phase 1 Trial of ORX142 for Neurological, Neurodegenerative Disorders - MarketScreener
Centessa Pharmaceuticals plc Announces Clearance of Investigational New Drug Application for ORX142 - MarketScreener
SEC Form N-CSRS filed by abrdn Life Sciences Investors Shares of Beneficial Interest - Quantisnow
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet - MSN
Centessa Pharmaceuticals Announces Executive Changes By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals Announces Executive Changes - Investing.com India
Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q1 Net Loss $0.20 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q1 License and Other Revenue of $15M - marketscreener.com
Is Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) A Suitable Stock For New Investors Today? - Stocksregister
Ratios in Focus: Analyzing Centessa Pharmaceuticals plc ADR (CNTA)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Investor’s Delight: Centessa Pharmaceuticals plc ADR (CNTA) Closes Weak at 13.50, Down -1.53 - DWinneX
Was Centessa Pharmaceuticals plc ADR (CNTA)’s session last reading good? - uspostnews.com
Top investors say Centessa Pharmaceuticals plc ADR (CNTA) ticks everything they need - Sete News
Investor’s Toolkit: Key Ratios for Assessing MSCI Inc (MSCI)’s Performance - DWinneX
Financial Metrics Check: Centessa Pharmaceuticals plc ADR (CNTA)’s Ratios for Trailing Twelve Months - DWinneX
Should investors be concerned about Centessa Pharmaceuticals plc ADR (CNTA)? - uspostnews.com
Parsons Corp (PSN) Shares Up Despite Recent Market Volatility - News Heater
Lantheus Holdings Inc [LNTH] Insider Activity: An Update for Investors - knoxdaily.com
Piper Sandler Initiates Centessa Pharmaceuticals at Overweight With $38 Price Target - MarketScreener
Centessa Pharmaceuticals chief business officer sells $163,386 in stock - Investing.com
Centessa Pharmaceuticals CEO sells shares worth $918,060 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals CEO sells shares worth $918,060 - Investing.com India
Centessa Pharmaceuticals CAO sells shares worth $120,205 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals CAO sells shares worth $120,205 - Investing.com India
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s Stock Boosts 3.25%, But It May Be A Worthy Investment - Stocks Register
Ratios Revealed: Decoding Centessa Pharmaceuticals plc ADR (CNTA)’s Financial Health - The Dwinnex
Centessa Pharmaceuticals officer sells shares worth $588,943 - Investing.com India
Centessa Pharmaceuticals officer Tia Bush sells $185,406 in shares - Investing.com
Centessa Pharmaceuticals chief business officer sells shares worth $193,429 - Investing.com India
Form N-CSR FIDELITY CONCORD STREET For: Nov 30 - StreetInsider.com
Centessa Pharmaceuticals general counsel Hussain Iqbal sells $91,740 in shares - Investing.com
Centessa Pharmaceuticals appoints new Chief Medical Officer - Investing.com
Centessa Pharmaceuticals' chief business officer sells shares worth $170,399 - Investing.com
Finanzdaten der Centessa Pharmaceuticals Plc Adr-Aktie (CNTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):